Kidney Disease in Patients with Lupus Who Are Treated with Potent Drugs that Suppress the Immune System
Journal: Annals of Internal Medicine (2001)

Summaries for Patients21 August 2001Kidney Disease in Patients with Lupus Who Are Treated with Potent Drugs that Suppress the Immune SystemSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-135-4-200108210-00003 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail What is the problem and what is known about it so far?Lupus is a disease of the immune system that can damage many body organs. Damage to the kidneys from this disease is known as lupus nephritis. Lupus nephritis is difficult to treat and can return even if initial treatment is successful. If left untreated, lupus nephritis can progress to complete kidney failure. Patients with kidney failure need kidney transplantation or hemodialysis (a procedure in which a special machine filters the blood). Treatment of lupus nephritis often includes two powerful drugs that suppress the immune system: methylprednisolone and cyclophosphamide. ... Author, Article, and Disclosure InformationThe summary below is from the full report titled “Combination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis.” It is in the 21 August 2001 issue of Annals of Internal Medicine (volume 135, pages 248-257). The authors are GG Illei, HA Austin III, M Crane, L Collins, MF Gourley, CH Yarboro, EM Vaughan, T Kuroiwa, CL Danning, AD Steinberg, JH Klippel, JE Balow, and DT Boumpas.Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoCombination Therapy with Pulse Cyclophosphamide plus Pulse Methylprednisolone Improves Long-Term Renal Outcome without Adding Toxicity in Patients with Lupus Nephritis Gabor G. Illei , Howard A. Austin III , Marianna Crane , Lee Collins , Mark F. Gourley , Cheryl H. Yarboro , Ellen M. Vaughan , Takashi Kuroiwa , Carol L. Danning , Alfred D. Steinberg , John H. Klippel , James E. Balow , and Dimitrios T. Boumpas Metrics 21 August 2001Volume 135, Issue 4Page: I-29KeywordsAdverse reactionsCyclophosphamideDrugsHeart rateImmune systemKidneysLupus nephritisRenal diseasesRenal failureRenal transplantation ePublished: 21 August 2001 Issue Published: 21 August 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...